Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures

Journal of Hepatology

Volumn 47, Issue 5, 2007, Pages 677-683

  Lempinen, Marko ^a   Isoniemi, Helena ^a   Mäkisalo, Heikki ^a   Nordin, Arno ^a   Halme, Leena ^a   Arola, Johanna ^b   Höckerstedt, Krister ^a   Stenman, Ulf Håkan ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

CA19 9; Cholangiocarcinoma; PSC; Trypsinogen 2; Tumour markers

Indexed keywords

ALPHA 1 ANTITRYPSIN; APROTININ; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; TRYPSIN; TRYPSIN 2; TRYPSINOGEN; TRYPSINOGEN 1; TRYPSINOGEN 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; CONCENTRATION (PARAMETERS); DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; EARLY DIAGNOSIS; EVALUATION; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNOFLUORESCENCE; LIVER CIRRHOSIS; LIVER SURGERY; MAJOR CLINICAL STUDY; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CA-19-9 ANTIGEN; CHOLANGIOCARCINOMA; CONSTRICTION, PATHOLOGIC; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECEPTORS, CELL SURFACE; SENSITIVITY AND SPECIFICITY; TRYPSIN; TRYPSINOGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 34848886866     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.05.017     Document Type: Article

References (47)

1. LaRusso N.F., Shneider B.L., Black D., Gores G.J., James S.P., Doo E., et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology 44 (2006) 746-764
2. Bergquist A., Ekbom A., Olsson R., Kornfeldt D., Lööf L., Danielsson A., et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 36 (2002) 321-327
3. Burak K., Angulo P., Pasha T.M., Egan K., Petz J., and Lindor K.D. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 99 (2004) 523-526
4. Broome U., Olsson R., Lööf L., Bodemar G., Hultcrantz R., Danielsson A., et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 38 (1996) 610-615
5. Chalasani N., Baluyut A., Ismail A., Zaman A., Sood G., Ghalib R., et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 31 (2000) 7-11
6. Lazaridis K.N., and Gores G.J. Primary sclerosing cholangitis and cholangiocarcinoma. Semin Liver Dis 26 (2006) 42-51
7. Brandsaeter B., Isoniemi H., Broome U., Olausson M., Backman L., Hansen B., et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 40 (2004) 815-822
8. Gores G.J. Early detection and treatment of cholangiocarcinoma. Liver Transplant 6 (2000) S30-S34
9. Keiding S., Hansen S.B., Rasmussen H.H., Gee A., Kruse A., Roelsgaard K., et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology 28 (1998) 700-706
10. Fevery J., Buchel O., Nevens F., Verslype C., Stroobants S., and Van Steenbergen W. Positron emission tomography is not a reliable method for the early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 43 (2005) 358-360
11. Kocjan G., and Smith A.N. Bile duct brushings cytology: potential pitfalls in diagnosis. Diagn Cytopathol 16 (1997) 358-363
12. Boberg K.M., and Schrumpf E. Diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep 6 (2004) 52-59
13. Baskin-Bey E.S., Moreno Luna L.E., and Gores G.J. Diagnosis of cholangiocarcinoma in patients with PSC: a sight on cytology. J Hepatol 45 (2006) 476-479
14. Duffy M.J. CA 19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem 35 (1998) 364-370
15. Ramage J.K., Donaghy A., Farrant J.M., Iorns R., and Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology 108 (1995) 865-869
16. Patel A.H., Harnois D.M., Klee G.G., LaRusso N.F., and Gores G.J. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 95 (2000) 204-207
17. Duffy M.J. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?. Clin Chem 47 (2001) 624-630
18. Stenman U.H., Alfthan H., and Hotakainen K. Human chorionic gonadotropin in cancer. Clin Biochem 37 (2004) 549-561
19. Louhimo J., Finne P., Alfthan H., Stenman U.H., and Haglund C. Combination of HCGbeta, CA 19-9 and CEA with logistic regression improves accuracy in gastrointestinal malignancies. Anticancer Res 22 (2002) 1759-1764
20. Paju A., and Stenman U.H. Biochemistry and clinical role of trypsinogens and pancreatic secretory trypsin inhibitor. Crit Rev Clin Lab Sci 43 (2006) 103-142
21. Koivunen E., Ristimäki A., Itkonen O., Osman S., Vuento M., and Stenman U.H. Tumor-associated trypsin participates in cancer cell-mediated degradation of extracellular matrix. Cancer Res 51 (1991) 2107-2112
22. Terada T., Ohta T., Minato H., and Nakanuma Y. Expression of pancreatic trypsinogen/trypsin and cathepsin B in human cholangiocarcinomas and hepatocellular carcinomas. Hum Pathol 26 (1995) 746-752
23. Oyama K., Ohta T., Nishimura G.I., Elnemr A., Yasui T., Fujimura T., et al. Trypsinogen expression in colorectal cancers. Int J Mol Med 6 (2000) 543-548
24. Fujimura T., Ohta T., Kitagawa H., Fushida S., Nishimura G.I., Yonemura Y., et al. Trypsinogen expression and early detection for peritoneal dissemination in gastric cancer. J Surg Oncol 69 (1998) 71-75
25. Ohta T., Terada T., Nagakawa T., Tajima H., Itoh H., Fonseca L., et al. Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesions. Br J Cancer 69 (1994) 152-156
26. Koivunen E., Itkonen O., Halila H., and Stenman U.H. Cyst fluid of ovarian cancer patients contains high concentrations of trypsinogen-2. Cancer Res 50 (1990) 2375-2378
27. Koivunen E., Huhtala M.L., and Stenman U.H. Human ovarian tumor-associated trypsin. Its purification and characterization from mucinous cyst fluid and identification as an activator of pro-urokinase. J Biol Chem 264 (1989) 14095-14099
28. Hedström J., Haglund C., Haapiainen R., and Stenman U.H. Serum trypsinogen-2 and trypsin-2-alpha(1)-antitrypsin complex in malignant and benign digestive-tract diseases. Preferential elevation in patients with cholangiocarcinomas. Int J Cancer 66 (1996) 326-331
29. Stenman U.H., Huhtala M.L., Koistinen R., and Seppälä M. Immunochemical demonstration of an ovarian cancer-associated urinary peptide. Int J Cancer 30 (1982) 53-57
30. Kazal L.A., Spicer D.S., and Brahinsky R.A. Isolation of crystalline trypsin inhibitor-anticoagulant protein from pancreas. J Am Chem Soc 70 (1948) 3034-3040
31. Stenman U.H. Tumor-associated trypsin inhibitor. Clin Chem 48 (2002) 1206-1209
32. Lempinen M., Stenman U.H., Puolakkainen P., Hietaranta A., Haapiainen R., and Kemppainen E. Sequential changes in pancreatic markers in acute pancreatitis. Scand J Gastroenterol 38 (2003) 666-675
33. Ogawa M., Shibata T., Niinobu T., Uda K., Takata N., and Mori T. Serum pancreatic secretory trypsin inhibitor (PSTI) in patients with inflammatory diseases. Adv Exp Med Biol 240 (1988) 505-508
34. Tonouchi A., Ohtsuka M., Ito H., Kimura F., Shimizu H., Kato M., et al. Relationship between pancreatic secretory trypsin inhibitor and early recurrence of intrahepatic cholangiocarcinoma following surgical resection. Am J Gastroenterol 101 (2006) 1601-1610
35. Itkonen O., Koivunen E., Hurme M., Alfthan H., Schröder T., and Stenman U.H. Time-resolved immunofluorometric assays for trypsinogen-1 and 2 in serum reveal preferential elevation of trypsinogen-2 in pancreatitis. J Lab Clin Med 115 (1990) 712-718
36. Hedström J., Leinonen J., Sainio V., and Stenman U.H. Time-resolved immunofluorometric assay of trypsin-2 complexed with alpha 1-antitrypsin in serum. Clin Chem 40 (1994) 1761-1765
37. Hedström J., Haglund C., Kemppainen E., Leinimaa M., Leinonen J., and Stenman U.H. Time-resolved immunofluorometric assay of trypsin-1 complexed with alpha(1)-antitrypsin in serum: increased immunoreactivity in patients with biliary tract cancer. Clin Chem 45 (1999) 1768-1773
38. Osman S., Turpeinen U., Itkonen O., and Stenman U.H. Optimization of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor (TATI) using the streptavidin-biotin system. J Immunol Methods 161 (1993) 97-106
39. Alfthan H., and Stenman U.H. Falsely low results obtained with the Hybritech Tandem-R PSA assay. Clin Chem 34 (1988) 2152
40. Alfthan H., Haglund C., Dabek J., and Stenman U.H. Concentrations of human choriogonadotropin, its beta-subunit, and the core fragment of the beta-subunit in serum and urine of men and nonpregnant women. Clin Chem 38 (1992) 1981-1987
41. De Vreede I., Steers J.L., Burch P.A., Rosen C.B., Gunderson L.L., Haddock M.G., et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transplant 6 (2000) 309-316
42. Rea D.J., Heimbach J.K., Rosen C.B., Haddock M.G., Alberts S.R., Kremers W.K., et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 242 (2005) 451-458 [discussion 458-61]
43. Terada T., and Nakanuma Y. Immunohistochemical demonstration of pancreatic alpha-amylase and trypsin in intrahepatic bile ducts and peribiliary glands. Hepatology 14 (1991) 1129-1135
44. Levy C., Lymp J., Angulo P., Gores G.J., Larusso N., and Lindor K.D. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 50 (2005) 1734-1740
45. Louhimo J., Nordling S., Alfthan H., von Boguslawski K., Stenman U.H., and Haglund C. Specific staining of human chorionic gonadotropin beta in benign and malignant gastrointestinal tissues with monoclonal antibodies. Histopathology 38 (2001) 418-424
46. Terada T., Kida T., and Nakanuma Y. Extrahepatic peribiliary glands express alpha-amylase isozymes, trypsin and pancreatic lipase: an immunohistochemical analysis. Hepatology 18 (1993) 803-808
47. Sun Z., and Yang P. Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. Lancet Oncol 5 (2004) 182-190